ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 163 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $14,550,000 | +29593.9% | 2,412,979 | +13033.3% | 0.11% | – |
| Q2 2019 | $49,000 | -3.9% | 18,373 | +7.5% | 0.00% | – |
| Q1 2019 | $51,000 | -72.7% | 17,091 | -85.5% | 0.00% | -100.0% |
| Q4 2018 | $187,000 | -36.6% | 117,528 | +46.5% | 0.00% | 0.0% |
| Q3 2018 | $295,000 | +13.9% | 80,206 | -12.4% | 0.00% | +100.0% |
| Q2 2018 | $259,000 | +97.7% | 91,511 | +159.2% | 0.00% | – |
| Q1 2018 | $131,000 | +33.7% | 35,300 | +180.2% | 0.00% | – |
| Q2 2016 | $98,000 | -66.0% | 12,600 | -66.2% | 0.00% | -100.0% |
| Q1 2016 | $288,000 | +260.0% | 37,300 | +314.4% | 0.00% | – |
| Q2 2015 | $80,000 | -23.8% | 9,000 | -15.1% | 0.00% | -100.0% |
| Q1 2015 | $105,000 | -97.9% | 10,600 | -97.4% | 0.00% | -96.6% |
| Q4 2014 | $5,034,000 | -21.2% | 410,900 | -35.8% | 0.03% | -34.1% |
| Q3 2014 | $6,389,000 | +566.2% | 640,273 | +405.3% | 0.04% | +450.0% |
| Q2 2014 | $959,000 | +356.7% | 126,710 | +98.9% | 0.01% | +300.0% |
| Q1 2014 | $210,000 | +328.6% | 63,700 | +290.8% | 0.00% | – |
| Q3 2013 | $49,000 | – | 16,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 12,033,220 | $92,896,000 | 11.87% |
| RTW INVESTMENTS, LP | 2,558,859 | $19,754,000 | 7.17% |
| TURNER INVESTMENTS LLC | 859,560 | $6,636,000 | 1.80% |
| DAFNA Capital Management LLC | 236,500 | $1,826,000 | 1.58% |
| Ghost Tree Capital, LLC | 250,000 | $1,930,000 | 1.09% |
| Orbimed Advisors | 11,519,700 | $88,932,000 | 0.94% |
| Rock Springs Capital Management LP | 1,220,000 | $9,418,000 | 0.79% |
| Opus Point Partners Management, LLC | 99,000 | $764,000 | 0.59% |
| Bellevue Group AG | 420,000 | $3,242,000 | 0.59% |
| Cormorant Asset Management, LP | 500,000 | $3,860,000 | 0.58% |